1.57p-0.01 (-0.32%)22 Nov 2024, 15:33
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Immupharma PLC Fundamentals

Company NameImmupharma PLCLast Updated2024-11-22
IndustryBiotechnologySectorHealthcare
Shares in Issue416.437 mMarket Cap£6.52 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.01EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.5096Cash Equity Ratio0.4030
Quick Ratio1.0450Current Ratio1.60
Price To Book Value2.4219ROCE0

Immupharma PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Immupharma PLC Company Financials

Assets202320222021
Tangible Assets£102,075.00£389,718.00£352,996.00
Intangible Assets£447,571.00£473,892.00£477,553.00
Investments£643,781.00£688,350.00£1.21 m
Total Fixed Assets£1.38 m£1.64 m£2.65 m
Stocks000
Debtors£451,546.00£649,401.00£373,253.00
Cash & Equivalents£208,481.00£667,813.00£1.65 m
Other Assets£184,785.00£83,790.00£612,997.00
Total Assets£2.72 m£3.97 m£6.00 m
Liabilities202320222021
Creditors within 1 year£1.67 m£1.45 m£1.58 m
Creditors after 1 year000
Other Liabilities000
Total Liabilities£1.67 m£1.45 m£1.58 m
Net assets£1.06 m£2.52 m£4.41 m
Equity202320222021
Called up share capital£29.81 m£28.98 m£28.50 m
Share Premium£29.32 m£28.79 m£27.24 m
Profit / Loss-£3.42 m-£4.46 m-£8.94 m
Other Equity£1.06 m£2.52 m£4.41 m
Preference & Minorities000
Total Capital Employed£1.06 m£2.52 m£4.41 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.50961.50961.5096
Cash / Equity0.40300.40300.4030
EPS-£0.01-£0.01-£0.02
Cash Flow202320222021
Cash from operating activities-£1.36 m-£2.35 m-£4.83 m
Cashflow before financing-£642,311.00-£799,335.00-£4.13 m
Increase in Cash-£453,549.00-£876,759.00-£4.18 m
Income202320222021
Turnover00£118,350.00
Cost of sales000
Gross Profit000
Operating Profit-£3.06 m-£3.03 m-£6.59 m
Pre-Tax profit-£3.42 m-£4.46 m-£8.94 m

Immupharma PLC Company Background

SectorHealthcare
ActivitiesImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.
Latest Interim Date9 Sep 2024
Latest Fiscal Year End Date5 Jun 2024

Immupharma PLC Directors

AppointedNamePosition
2021-07-30Dr. Franco Di MuzioNon-Executive Director
2006-03-31Mr. Douglas Gordon James PatersonNon-Executive Director
2024-03-19Mr. Timothy Paul McCarthyExecutive Director,Chairman and Chief Executive Officer
2021-07-30Mr. Dimitri DimitriouExecutive Director,Chief Executive Officer
2021-05-24Dr. Robert Henri ZimmerExecutive Director,President and Chief Scientific Officer
2016-05-05Mr. Richard Leonard WarrExecutive Director,Chairman
2016-05-05Dr. Ajay AgrawalNon-Executive Director
2011-08-09Mr. Paddy Hugh Walker-Taylor FCA,MCTExecutive Director,Chief Financial Officer
2006-03-31Mr. Anthony Johnson B.Pharm,MScNon-Executive Director
2023-08-11Dr. Sanjeev PandyaNon-Executive Director,Senior Independent Director
2021-07-30Dr. Stephane Robert George MeryNon-Executive Director
2024-03-19Mr. Timothy Gary FranklinExecutive Director,Chief Operating Officer
2024-04-19Ms. Lisa BaderoonNon-Executive Director

Immupharma PLC Contact Details

Company NameImmuPharma PLC
AddressOne Bartholomew Close, London, EC1A 7BL
Telephone+44 2071524080
Websitehttps://www.immupharma.co.uk

Immupharma PLC Advisors

StockbrokerBryan, Garnier & Co Limited
Phone+44 2073322500
Nominated AdviserNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
StockbrokerNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
RegistrarComputershare Investor Services PLC
Phone+44 3707020003
Fax+44 3707036101
AuditorNexia Smith & Williamson
Phone+44 2071314000
Fax+44 2071314001
SolicitorBircham Dyson Bell
Phone+44 2072277000
Fax+44 2072223480
BankRoyal Bank of Scotland PLC
AuditorNexia Smith & Williamson Audit Limited